6533b7dafe1ef96bd126e1f4

RESEARCH PRODUCT

Dysidotronic acid, a new sesquiterpenoid, inhibits cytokine production and the expression of nitric oxide synthase.

Maria Valeria D'auriaInmaculada PosadasMiguel PayáClelia GianniniM. Carmen Terencio

subject

Nitric oxide (NO)MouseLeukotriene B4NeutrophilsRAW 264.7Dysidotronic acidNitric Oxide Synthase Type IIDinoprostonePhospholipases ANitric oxideCell Linechemistry.chemical_compoundManoalideMicemedicineAnimalsHumansProstaglandin E2Enzyme InhibitorsCytokineNitritesPharmacologybiologyTumor Necrosis Factor-alphaMacrophagesZymosanZymosanMembrane ProteinsNitric oxide synthaseIsoenzymesAir pouchchemistryBiochemistryEnzyme inhibitorCyclooxygenase 2Prostaglandin-Endoperoxide Synthasesbiology.proteinCytokinesArachidonic acidDiterpenesNitric Oxide SynthaseSesquiterpenesmedicine.drug

description

In a previous study, we reported a new bioactive sesquiterpenoid, named dysidotronic acid, to be a potent, selective human synovial phospholipase A(2) inhibitor. Dysidotronic acid is a novel, non-complex manoalide analogue lacking the pyranofuranone ring. We now investigate the effect of this compound on cytokine, nitric oxide and prostanoid generation on the mouse macrophage cell line RAW 264.7, where it showed a dose-dependent inhibition with inhibitory concentration 50% values in the micromolar range. This effect was also confirmed in the mouse air pouch injected with zymosan. Dysidotronic acid inhibited the production of tumor necrosis factor alpha and interleukin-1 beta as well as the production of nitric oxide, prostaglandin E(2) and leukotriene B(4). Decreased nitric oxide generation was the consequence of inhibition of the expression of nitric oxide synthase, whereas PGE(2) and LTB(4) reduction was due to inhibition of arachidonic acid bioavailability through a direct inhibitory effect of dysodotronic acid on secretory phospholipase A(2).

10.1016/s0014-2999(01)00844-5https://pubmed.ncbi.nlm.nih.gov/11275011